<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED
        STATES</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
        AND EXCHANGE COMMISSION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON,
        D.C. 20549</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>FORM
        8-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CURRENT
        REPORT</font><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT
        TO SECTION 13 OR 15(</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        OF</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">THE
        SECURITIES EXCHANGE ACT OF 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
        of
        Report (Date of earliest event reported): October 24, 2005</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>Hana
        Biosciences, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
        name of registrant as specified in its charter)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div align="center">
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">&#160;</td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Delaware</font></div>
                </td>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">001-32626</font></div>
                </td>
                <td valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">84-1588441</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                    or other jurisdiction of<br>incorporation)</font></div>
                </td>
                <td valign="top" width="50%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission
                    File Number)</font></div>
                </td>
                <td valign="top" width="25%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(IRS
                    Employer<br>Identification No.)</font></div>
                </td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">&#160;</td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">&#160;</td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><strong><font size="2">400
                    Oyster Point Blvd., Ste. 215, South
                    San Francisco,&#160; CA</font></strong>&#160;</div>
                </td>
                <td valign="top" width="25%"><strong><font size="2">94080</font></strong>&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">(Address
                    of principal executive
                    offices)</font></div>
                </td>
                <td valign="top" width="25%"><font size="2">(Zip Code)</font>&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">&#160;</td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><strong><font size="2">(650)
                    588-6404</font></strong>&#160;</div>
                </td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">(Registrant's
                    telephone number, including area
                    code)</font>&#160;</div>
                </td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">&#160;</td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">
                  <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">(Former
                    name or former address, if changed since
                    last report)</font>&#160;</div>
                </td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">&#160;</td>
                <td valign="top" width="25%">&#160;</td>
              </tr>
              <tr>
                <td valign="top" width="25%">&#160;</td>
                <td valign="top" width="50%">&#160;</td>
                <td valign="top" width="25%">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
          the
          appropriate box below if the Form 8-K filing is intended to simultaneously
          satisfy the filing obligation of the registrant under any of the following
          provisions:</font></div>
      </div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="5%">&#160;</td>
              <td width="95%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%"><font style="FONT-FAMILY: Wingdings" size="2">o</font>&#160;</td>
              <td width="95%"><font size="2">Written communications pursuant to
                Rule 425
                under the Securities Act (17 CFR 230.425)</font>&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%"><font style="FONT-FAMILY: Wingdings" size="2">o</font>&#160;</td>
              <td width="95%"><font size="2">Soliciting material pursuant to Rule
                14a-12
                under the Exchange Act (17 CFR 240.14a-12)</font>&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%"><font style="FONT-FAMILY: Wingdings" size="2">o</font>&#160;</td>
              <td width="95%"><font size="2">Pre-commencement communications pursuant
                to
                Rule 14d-2(b) under the Exchange Act (17 CFR
                240.14d-2(b))</font>&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="5%"><font style="FONT-FAMILY: Wingdings" size="2">o</font>&#160;</td>
              <td width="95%"><font size="2">Pre-commencement communications pursuant
                to
                Rule 13e-4(c) under the Exchange Act (17 CFR
                240.13e-4(c))</font>&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
        3.02. Unregistered Sales of Securities. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to a Securities Purchase Agreement dated October 19, 2005 (the &#8220;Agreement&#8221;)
        among Hana Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;) and certain
        institutional and other accredited investors identified therein, on October
        24,
        2005, the Company completed the sale of an aggregate of 3,686,716 shares
        (the
&#8220;Shares&#8221;) of the Company&#8217;s common stock at a price of $4.00 per Share; provided,
        however that the purchase price was $4.59 per Share with respect to certain
        affiliates of the Company who purchased Shares in the private placement,
        as
        described below. In addition to the Shares, the Company also issued five-year
        warrants to purchase, at an exercise price of $5.80 per share, an additional
        737,343 shares of Common Stock. The Company previously disclosed the entry
        into
        the Agreement on its Current Report filed October 20, 2005.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Among
        the
        investors participating in the private placement were Mark J. Ahn (together
        with
        his spouse) and Fred L. Vitale, who purchased 10,892 and 43,572 Shares,
        respectively. Mr. Ahn is President and Chief Executive Officer and a director
        of
        the Company. Mr. Vitale is Vice President, Business Development of the Company.
        In addition, Coqui Capital Partners, L.P. and Kier Family, L.P. purchased
        54,466
        and 21,786 Shares, respectively. Isaac Kier, a director of the Company, is
        a
        limited partner of Coqui Capital Partners, L.P and the general partner of
        Kier
        Family, L.P. Notwithstanding the $4.00 offering price applicable to
        non-affiliated investors, the per Share purchase price paid by Messrs. Ahn,
        Vitale and by Coqui Capital Partners, L.P. and Kier Family, L.P. was $4.59,
        which was the last closing sale price of the Company&#8217;s common stock prior to
        entry into the Agreement. Each of such affiliated investors also received
        warrants to purchase an additional number of shares of common stock equal
        to 20
        percent of the Shares purchased, which warrants have the same terms as those
        received by the other investors in the offering.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company engaged Oppenheimer &amp; Co., Inc. and Griffin Securities, Inc.
        (together, the &#8220;Placement Agents&#8221;) as placement agents in connection with the
        private placement. In consideration for their services, the Company paid
        the
        Placement Agents aggregate cash commissions of $1,002,680 and issued 5-year
        warrants to the Placement Agents to purchase an aggregate of 213,703 shares
        at
        an exercise price of $5.80 per share. The Company also reimbursed the Placement
        Agents an aggregate of $60,000 for expenses they incurred in connection with
        the
        private placement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        sale
        of the Shares and Warrants was not registered under the Securities Act of
        1933,
        as amended (the &#8220;Securities Act&#8221;). Rather, the offer and sale of such securities
        was made in reliance on the exemption from registration requirements provided
        by
        Section 4(2) of the Securities Act and Regulation D promulgated thereunder.
        Each
        of the investors was &#8220;accredited&#8221; (as defined under Regulation D) and no general
        solicitation was used in connection with the offer and sale of such
        securities.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the Registrant
        has
        duly caused this report to be signed on its behalf by the undersigned hereunto
        duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <div>
          <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

              <tr valign="top" bgcolor="#ffffff">
                <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
                <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
                <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
                <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>HANA&#160;BIOSCIENCES,
                  INC.</strong></font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                  October 24, 2005&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Russell
                  L. Skibsted</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
                <td align="left">
                  <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Russell
                  L. Skibsted</font></td>
              </tr>
              <tr valign="top" bgcolor="#ffffff">
                <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
                <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                  Financial Officer</font></td>
              </tr>

          </table>
        </div><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
    </div>
  </body>
</html>
{"company-data": {"conformed-name": "Hana Biosciences Inc", "cik": "0001140028", "assigned-sic": "2834", "irs-number": "841588441", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32626", "film-number": "051153133"}, "business-address": {"street1": "400 OYSTER POINT BOULEVARD", "street2": "SUITE 215", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "6505886404"}, "mail-address": {"street1": "400 OYSTER POINT BOULEVARD", "street2": "SUITE 215", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080"}, "former-company": {"former-conformed-name": "EMAIL REAL ESTATE COM INC", "date-changed": "20010504"}}
Unassociated Document
UNITED
        STATES
SECURITIES
        AND EXCHANGE COMMISSION
WASHINGTON,
        D.C. 20549
FORM
        8-K
CURRENT
        REPORT
PURSUANT
        TO SECTION 13 OR 15(
d
)
        OF
THE
        SECURITIES EXCHANGE ACT OF 1934
Date
        of
        Report (Date of earliest event reported): October 24, 2005
Hana
        Biosciences, Inc.
(Exact
        name of registrant as specified in its charter)
Delaware
001-32626
84-1588441
(State
                    or other jurisdiction of
incorporation)
(Commission
                    File Number)
(IRS
                    Employer
Identification No.)
400
                    Oyster Point Blvd., Ste. 215, South
                    San Francisco,  CA
94080
(Address
                    of principal executive
                    offices)
(Zip Code)
(650)
                    588-6404
(Registrant's
                    telephone number, including area
                    code)
(Former
                    name or former address, if changed since
                    last report)
Check
          the
          appropriate box below if the Form 8-K filing is intended to simultaneously
          satisfy the filing obligation of the registrant under any of the following
          provisions:
o
Written communications pursuant to
                Rule 425
                under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
                14a-12
                under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
                to
                Rule 14d-2(b) under the Exchange Act (17 CFR
                240.14d-2(b))
o
Pre-commencement communications pursuant
                to
                Rule 13e-4(c) under the Exchange Act (17 CFR
                240.13e-4(c))
Item
        3.02. Unregistered Sales of Securities.
Pursuant
        to a Securities Purchase Agreement dated October 19, 2005 (the "Agreement")
        among Hana Biosciences, Inc., a Delaware corporation (the "Company") and certain
        institutional and other accredited investors identified therein, on October
        24,
        2005, the Company completed the sale of an aggregate of 3,686,716 shares
        (the
"Shares") of the Company's common stock at a price of $4.00 per Share; provided,
        however that the purchase price was $4.59 per Share with respect to certain
        affiliates of the Company who purchased Shares in the private placement,
        as
        described below. In addition to the Shares, the Company also issued five-year
        warrants to purchase, at an exercise price of $5.80 per share, an additional
        737,343 shares of Common Stock. The Company previously disclosed the entry
        into
        the Agreement on its Current Report filed October 20, 2005.
Among
        the
        investors participating in the private placement were Mark J. Ahn (together
        with
        his spouse) and Fred L. Vitale, who purchased 10,892 and 43,572 Shares,
        respectively. Mr. Ahn is President and Chief Executive Officer and a director
        of
        the Company. Mr. Vitale is Vice President, Business Development of the Company.
        In addition, Coqui Capital Partners, L.P. and Kier Family, L.P. purchased
        54,466
        and 21,786 Shares, respectively. Isaac Kier, a director of the Company, is
        a
        limited partner of Coqui Capital Partners, L.P and the general partner of
        Kier
        Family, L.P. Notwithstanding the $4.00 offering price applicable to
        non-affiliated investors, the per Share purchase price paid by Messrs. Ahn,
        Vitale and by Coqui Capital Partners, L.P. and Kier Family, L.P. was $4.59,
        which was the last closing sale price of the Company's common stock prior to
        entry into the Agreement. Each of such affiliated investors also received
        warrants to purchase an additional number of shares of common stock equal
        to 20
        percent of the Shares purchased, which warrants have the same terms as those
        received by the other investors in the offering.
The
        Company engaged Oppenheimer & Co., Inc. and Griffin Securities, Inc.
        (together, the "Placement Agents") as placement agents in connection with the
        private placement. In consideration for their services, the Company paid
        the
        Placement Agents aggregate cash commissions of $1,002,680 and issued 5-year
        warrants to the Placement Agents to purchase an aggregate of 213,703 shares
        at
        an exercise price of $5.80 per share. The Company also reimbursed the Placement
        Agents an aggregate of $60,000 for expenses they incurred in connection with
        the
        private placement.
The
        sale
        of the Shares and Warrants was not registered under the Securities Act of
        1933,
        as amended (the "Securities Act"). Rather, the offer and sale of such securities
        was made in reliance on the exemption from registration requirements provided
        by
        Section 4(2) of the Securities Act and Regulation D promulgated thereunder.
        Each
        of the investors was "accredited" (as defined under Regulation D) and no general
        solicitation was used in connection with the offer and sale of such
        securities.
SIGNATURE
Pursuant
        to the requirements of the Securities Exchange Act of 1934, the Registrant
        has
        duly caused this report to be signed on its behalf by the undersigned hereunto
        duly authorized.
HANA BIOSCIENCES,
                  INC.
Date:
                  October 24, 2005
By:
/s/ Russell
                  L. Skibsted
Russell
                  L. Skibsted
Chief
                  Financial Officer